Craft

Avacta Group

Stock Price

£0.5

2024-10-29

Market Capitalization

£203.4 M

2024-10-29

Revenue

£6.3 M

FY, 2025

Avacta Group Summary

Company Summary

Overview
Avacta Group plc is a provider of research reagents, consumables and equipment to the life sciences and animal care markets. The Company provides research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. It operates through three segments: Analytical, Animal Health and Life Sciences. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health segment provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Life Sciences segment provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. Its subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited and others.
Type
Public
Status
Active
Founded
2003
HQ
Wetherby, GB | view all locations
Website
http://www.avacta.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Tony Gardiner

    Tony Gardiner, Chief Financial Officer and Director

  • Trevor Nicholls

    Trevor Nicholls, Non Executive Director

  • Christina Coughlin

    Christina Coughlin, Chief Executive Officer & Director

  • Craig Slater

    Craig Slater, Chief Operating Officer, Diagnostics

LocationsView all

3 locations detected

  • Wetherby, England HQ

    United Kingdom

    Unit 20, Ash Way, Thorp Arch Estate & Retail Park

  • London, England

    United Kingdom

    200 Aldersgate St, Barbican

  • Whittlesford, England

    United Kingdom

    LION WORKS, Station Rd W

Avacta Group Financials

Summary Financials

Revenue (FY, 2025)
£6.3M
Gross profit (FY, 2025)
£3.0M
Net income (FY, 2025)
(£38.4M)
Cash (FY, 2025)
£16.9M
EBIT (FY, 2025)
(£31.8M)
Enterprise value
$211.2M

Footer menu